Axon Enterprise (NASDAQ:AXON) Research Coverage Started at TD Cowen

TD Cowen began coverage on shares of Axon Enterprise (NASDAQ:AXON) in a report released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $700.00 target price on the biotechnology company’s stock.

AXON has been the subject of a number of other research reports. JMP Securities boosted their price target on Axon Enterprise from $430.00 to $500.00 and gave the stock a “market outperform” rating in a report on Thursday, October 31st. The Goldman Sachs Group boosted their price target on Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC upped their target price on Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Robert W. Baird upped their target price on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Finally, Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $504.92.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $570.00 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a 52 week low of $246.99 and a 52 week high of $698.67. The stock has a market capitalization of $43.47 billion, a P/E ratio of 147.29, a price-to-earnings-growth ratio of 14.19 and a beta of 1.04. The stock has a fifty day moving average of $604.40 and a 200-day moving average of $446.90.

Insider Buying and Selling at Axon Enterprise

In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now owns 6,929 shares in the company, valued at $4,185,601.03. This represents a 6.10 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the sale, the director now owns 26,259 shares in the company, valued at approximately $11,500,916.82. The trade was a 3.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,545 shares of company stock worth $31,159,317. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Insigneo Advisory Services LLC boosted its holdings in Axon Enterprise by 1.4% in the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after acquiring an additional 22 shares in the last quarter. Menard Financial Group LLC boosted its holdings in Axon Enterprise by 0.8% in the third quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after acquiring an additional 24 shares in the last quarter. PFG Investments LLC boosted its holdings in Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after acquiring an additional 25 shares in the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in Axon Enterprise by 1.6% in the third quarter. Gladstone Institutional Advisory LLC now owns 1,641 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 26 shares in the last quarter. Finally, Mather Group LLC. boosted its holdings in Axon Enterprise by 3.7% in the third quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock worth $303,000 after acquiring an additional 27 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.